Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Improving Maternal Nutrition in Matlab (IMNiM)

In-home, Intensive Nutrition Counseling to Improve Gestational Weight Gain in Rural Bangladesh: A Cluster-Randomized Controlled Trial

Background: Maternal undernutrition and inadequate gestational weight gain (GWG) are prevalent in rural communities of low- and middle-income countries (LMICs). In Matlab, Bangladesh, 54% of the women fail to gain adequate weight (>4 kg) in the third trimester. Risks associated with inadequate GWG include giving birth to a small-for-gestational age (SGA) infant, low birth weight (LBW) infant, preterm birth (PTB), etc. Few contemporary studies examined the efficacy of nutrition counseling on GWG improvement in LMICs.

Objectives: The primary objective of this study is to assess whether in-home, intensive nutrition counseling during pregnancy, compared to standard antenatal care, could improve GWG among pregnant women in rural Bangladesh.

Methods: This prospective, two-arm, parallel group, equal allocation, open-label, community-based, cluster-randomized controlled trial will be conducted in the icddr,b service area of Matlab, a rural subdistrict of Bangladesh. Clusters will be randomly allocated 1:1 to the intervention arm in which pregnant women will receive monthly in-home, intensive nutrition counseling or the control arm in which pregnant women will receive standard antenatal care as offered by icddr,b and Govt. facilities. Fixed Site Clinics (FSCs) located at the homes of the community health research workers (CHRWs) will act as clusters. Of the 33 FSCs serving rural areas in the icddr,b service area, 20 will be selected randomly and listed. These 20 clinics will then be randomly allocated 1:1 to either an intervention or control group using a computer-generated random allocation sequence. To fulfil the required sample size, each selected CHRW will enroll 16 consecutive pregnancies. Required sample size is 16 women per cluster i.e. 160 women per arm. Eligible participants will be enrolled upon obtaining their consent by 13 and 6/7 weeks of gestation (first trimester) and followed up to 6 weeks postpartum. Trained health workers will visit the homes of the women in the intervention arm once a month and provide nutrition counseling to the women and her influential family members such as mothers, mothers-in-law and husbands. Both intention-to-treat and per-protocol analyses will be performed.

Outcome measures/variables: Proportion of women with inadequate rate of weight gain in the second and third trimester of pregnancy according to the US Institute of Medicine (IOM) 2009 guidelines is the primary outcome variable.

Panoramica dello studio

Stato

Attivo, non reclutante

Tipo di studio

Interventistico

Iscrizione (Effettivo)

287

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Chandpur, Bangladesh
        • International Centre for Diarrhoeal Disease Research, Bangladesh

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 39 anni (Adulto)

Accetta volontari sani

Sessi ammissibili allo studio

Femmina

Descrizione

Pregnant women permanently residing in the icddr,b service area of Matlab fulfilling the following criteria:

Inclusion Criteria:

  • aged 18-39 years
  • in the first trimester of pregnancy (before 14 weeks of gestation)
  • BMI 16-24.99 kg/m^2 measured on enrollment
  • willing to participate in the study

Exclusion criteria

  • multiple pregnancy (carrying two or more fetuses)
  • threatened abortion, persistent pervaginal bleeding, or cervical incompetence
  • history of three or more consecutive abortions
  • history of gestational diabetes, macrosomia, gestational hypertension, preeclampsia/eclampsia in a prior pregnancy
  • chronic diseases, such as hypertension, heart disease, chronic obstructive pulmonary disease, chronic kidney disease, chronic liver disease, pancreatic diseases, Crohn's disease, ulcerative colitis, diabetes mellitus, thyroid dysfunction, immunological diseases, malignancy or any other diseases which could impede compliance with the study protocol
  • taking medications known to influence fetal growth, such as insulin, thyroid hormones, glucocorticoids
  • known case of serious psychiatric or behavioral disorders, such as schizophrenia, bipolar disorder
  • scored as moderate or worse on enrollment on any one of the subscales of the Depression, Anxiety and Stress Scales-21 (DASS-21)
  • inability to read or write Bengali
  • belonging to moderately or severely food insecure households as measured by the Household Food Insecurity Access Scale (HFIAS)
  • having a plan to move or deliver outside the study area
  • women practicing some form of vegetarianism
  • women belonging to a household from which another woman is already enrolled in the study

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Ricerca sui servizi sanitari
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Intervention
In this arm, pregnant women, along with their influential family members such as mothers, mothers-in-law, and husbands, will receive monthly in-home, intensive nutrition counseling during the prenatal period.
  • Individualized sessions will be conducted by trained health workers following a standard document (counseling booklet)
  • The messages to be provided through the counseling will be contextualized
  • Sessions will start from the early second trimester and repeat monthly until 36 weeks of gestation
  • Counseling sessions will be conducted at the participant's place
  • Sessions will involve influential family members such as the husband, mother-in-law, mother, and the household head along with the pregnant women
  • Women will receive personalized feedback on their dietary intake pattern (dietary diversity) and the rate of weight gain in each session
  • Sessions will be tailored according to each participant's need and progress
Nessun intervento: Control
Pregnant women in this arm will receive standard antenatal care.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
proportion of women with inadequate rate of weight gain in the second and third trimester of pregnancy according to IOM 2009 guidelines
Lasso di tempo: Pre-delivery
Pregnancy trimesters are defined as follows: 1st trimester (0 weeks - 13+6 weeks), 2nd trimester (14 completed weeks - 27+6 weeks), and 3rd trimester (28 completed weeks - childbirth). Rate of weight gain between two time points (trimesters) will be calculated by subtracting the weight measured at the first time point from the weight measured at the second time point and dividing the derived value by the difference in weeks between the two time points.
Pre-delivery

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
total gestational weight gain (kg)
Lasso di tempo: pre-delivery
pre-delivery
rate of weight gain during the 2nd and 3rd trimester (kg/week)
Lasso di tempo: pre-delivery
pre-delivery
proportion of women with inadequate total GWG according to IOM criteria
Lasso di tempo: pre-delivery
pre-delivery
proportion of women with inadequate total GWG according to local criteria
Lasso di tempo: pre-delivery
pre-delivery
proportion of women with inadequate third trimester weight gain according to local criteria
Lasso di tempo: pre-delivery
pre-delivery
proportion of preterm births
Lasso di tempo: at delivery
childbirth before 37 completed weeks
at delivery
maternal mid-upper arm circumference (MUAC) (mm)
Lasso di tempo: baseline, 36 weeks of gestation, at delivery and 6 weeks post-partum
baseline, 36 weeks of gestation, at delivery and 6 weeks post-partum
maternal weight (kg)
Lasso di tempo: baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
maternal body mass index (BMI) (kg/m^2)
Lasso di tempo: baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
weight and height (at baseline) will be combined to report BMI
baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
infant weight (g)
Lasso di tempo: at birth (delivery) and after 4 weeks
at birth (delivery) and after 4 weeks
infant length (cm)
Lasso di tempo: at birth (delivery) and after 4 weeks
at birth (delivery) and after 4 weeks
infant head circumference (cm)
Lasso di tempo: at birth (delivery) and after 4 weeks
at birth (delivery) and after 4 weeks
proportion of low birth weight (< 2500 g) infants
Lasso di tempo: at birth (delivery)
at birth (delivery)
proportion of small for gestational age (<10th percentile) infants according to Intergrowth-21st standards
Lasso di tempo: at birth (delivery)
at birth (delivery)
proportion of women with pregnancy complications e.g. anemia, preeclampsia
Lasso di tempo: at delivery
at delivery
proportion of women with obstetric complications e.g. induction of labor, caesarean section
Lasso di tempo: at delivery
at delivery
newborn Apgar score
Lasso di tempo: at birth (delivery)
at birth (delivery)
proportion of infants developing morbidity
Lasso di tempo: 4 weeks after birth
4 weeks after birth
proportion of infant mortality
Lasso di tempo: 4 weeks after birth
4 weeks after birth
dietary diversity score according to the "Guidelines for Measuring Household and Individual Dietary Diversity"
Lasso di tempo: baseline, 36 weeks of gestation and 6 weeks post-partum
score range: 0-9; higher scores indicate a better outcome
baseline, 36 weeks of gestation and 6 weeks post-partum
dietary diversity score according to the "Minimum Dietary Diversity for Women: A Guide to Measurement"
Lasso di tempo: baseline, 36 weeks of gestation and 6 weeks post-partum
score range: 0-10; higher scores indicate a better outcome
baseline, 36 weeks of gestation and 6 weeks post-partum
proportion of women with inadequate dietary diversity accroding to the "Minimum Dietary Diversity for Women: A Guide to Measurement"
Lasso di tempo: baseline, 36 weeks of gestation and 6 weeks post-partum
score range: 0-10; <5 indicates inadequate dietary diversity
baseline, 36 weeks of gestation and 6 weeks post-partum
energy consumption (kcal)
Lasso di tempo: baseline, 36 weeks of gestation and 6 weeks post-partum
baseline, 36 weeks of gestation and 6 weeks post-partum
protein consumption (g)
Lasso di tempo: baseline, 36 weeks of gestation and 6 weeks post-partum
baseline, 36 weeks of gestation and 6 weeks post-partum
proportion of women with symptoms of depression as measured by Depression, Anxiety, and Stress Scales-21 (DASS-21) scales
Lasso di tempo: baseline, 36 weeks of gestation and 6 weeks post-partum
DASS-21 is a validated, widely used, standardized self-report scale with 7 items in each subscale category of Depression, Anxiety, and Stress symptoms. Responses are scored on a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much/most of the time), with higher scores indicating higher levels of depression, anxiety or stress.
baseline, 36 weeks of gestation and 6 weeks post-partum
proportion of women with symptoms of anxiety as measured by Depression, Anxiety, and Stress Scales-21 (DASS-21) scales
Lasso di tempo: baseline, 36 weeks of gestation and 6 weeks post-partum
DASS-21 is a validated, widely used, standardized self-report scale with 7 items in each subscale category of Depression, Anxiety, and Stress symptoms. Responses are scored on a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much/most of the time), with higher scores indicating higher levels of depression, anxiety or stress.
baseline, 36 weeks of gestation and 6 weeks post-partum
proportion of women with symptoms of stress as measured by Depression, Anxiety, and Stress Scales-21 (DASS-21) scales
Lasso di tempo: baseline, 36 weeks of gestation and 6 weeks post-partum
DASS-21 is a validated, widely used, standardized self-report scale with 7 items in each subscale category of Depression, Anxiety, and Stress symptoms. Responses are scored on a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much/most of the time), with higher scores indicating higher levels of depression, anxiety or stress.
baseline, 36 weeks of gestation and 6 weeks post-partum
healthcare seeking and services utilization e.g. number of prenatal visits
Lasso di tempo: at delivery
at delivery

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: S. M. Tafsir Hasan, MBBS, MS, Nutrition and Clinical Services Division, icddr,b

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

15 gennaio 2020

Completamento primario (Anticipato)

30 settembre 2021

Completamento dello studio (Anticipato)

31 ottobre 2021

Date di iscrizione allo studio

Primo inviato

28 dicembre 2019

Primo inviato che soddisfa i criteri di controllo qualità

27 aprile 2021

Primo Inserito (Effettivo)

3 maggio 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 maggio 2021

Ultimo aggiornamento inviato che soddisfa i criteri QC

27 aprile 2021

Ultimo verificato

1 aprile 2021

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Aumento di peso gestazionale

Sottoscrivi